Floatz logo

Polatuzumab

Mantle-cell Lymphoma

Medical University of ViennaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

172 Active assets in the Mantle-cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Polatuzumab is also rated in:

Aggressive Non-Hodgkin LymphomaDormant
B
Indicative ·
60 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
58 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →